BMS presented data from the CheckMate-8HW trial, demonstrating that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves outcomes for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) mCRC. The dual therapy:
- Reduced the risk of disease progression or death by 38% compared to Opdivo alone.
- Achieved a median progression-free survival of 39.3 months, compared to 47 months of follow-up where many patients remained progression-free.
- Previously demonstrated a 79% reduction in tumor progression compared to chemotherapy alone in first-line patients.